Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

原発性免疫不全症治療の世界市場2017-2021:イムノグロブリン治療、抗生物質、その他

◆タイトル:Global Primary Immunodeficiency Diseases Treatment Market 2017-2021
◆商品コード:IRTNTR14555
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年10月13日
◆ページ数:77
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、原発性免疫不全症治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、原発性免疫不全症治療の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は原発性免疫不全症治療の世界市場が2017-2021年期間中に年平均6.13%成長すると予測しています。当レポート上に記載されている主な企業は、CSL Behring、Grifols、Pfizer、Shire等です。

・エグゼクティブサマリー
・原発性免疫不全症治療の世界市場:市場概観
・原発性免疫不全症治療の世界市場:業界の構造分析
・原発性免疫不全症治療の世界市場:市場規模及び予測
・原発性免疫不全症治療の世界市場:地域別分析
・原発性免疫不全症治療の世界市場:アジア市場規模
・原発性免疫不全症治療の世界市場:アメリカ市場規模
・原発性免疫不全症治療の世界市場:ヨーロッパ市場規模
・原発性免疫不全症治療の世界市場:成長要因
・原発性免疫不全症治療の世界市場:課題
・原発性免疫不全症治療の世界市場:製品パイプライン分析
・原発性免疫不全症治療の世界市場:市場動向
・原発性免疫不全症治療の世界市場:競争状況
・原発性免疫不全症治療の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Primary Immunodeficiency Diseases Treatment
Primary immunodeficiency diseases or PIDDs are disorders where part of the body’s immune system is missing or not functioning properly. They weaken the body’s immune system, making the patient susceptible to infections and other health problems. Treatment is palliative and includes boosting the immune system, thereby helping the patient live a normal life. The major drug classes used for the treatment and management of the disease are immunoglobulins, antibiotics, and others.

Technavio’s analysts forecast the global primary immunodeficiency diseases treatment market to grow at a CAGR of 6.13% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global primary immunodeficiency diseases treatment market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Primary Immunodeficiency Diseases Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CSL Behring
• Grifols
• Pfizer
• Shire

[Other prominent vendors]
• Abbott
• ADMA Biologics
• Astellas
• AstraZeneca
• Baxter
• Bayer
• Biocon
• Bristol-Myers Squibb
• BDI Pharma
• Bharat Serums and Vaccines
• Eli Lilly
• GlaxoSmithKline
• Hualan Biological Engineering
• Kedrion Biopharma
• LFB Group
• Lupin Pharmaceuticals
• Mylan
• Novartis
• Octapharma
• Sanofi
• Sanquin
• Takeda Pharmaceutical Company
• Valneva
• Wockhardt

[Market driver]
• Growing number of fractionating units
• For a full, detailed list, view our report

[Market challenge]
• High cost of treatment
• For a full, detailed list, view our report

[Market trend]
• Shift of manufacturing facilities to low-cost regions
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by therapy
• Immunoglobulin therapy
• Antibiotics
• Others

PART 08: Geographical segmentation
• PIDDs treatment market in Americas
• PIDDs treatment market in EMEA
• PIDDs treatment market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Shift of manufacturing facilities to low-cost regions
• Financial aid to plasma donors

PART 12: Vendor landscape

PART 13: Key vendor analysis
• CSL Behring
• Grifols
• Pfizer
• Shire
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits] 
Exhibit 01: Features of PIDDs
Exhibit 02: Signs and symptoms of PI
Exhibit 03: PIDDs classification based on affected immune system
Exhibit 04: Diagnosis and treatment of PI
Exhibit 05: Global PIDDs treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of global PIDDs treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline analysis of vendors in global PIDDs treatment market
Exhibit 09: Key clinical trials
Exhibit 10: Market segmentation by therapy
Exhibit 11: Global PIDDs treatment market by immunoglobulin therapy 2016-2021 ($ millions)
Exhibit 12: Global PIDDs treatment market by antibiotics 2016-2021 ($ millions)
Exhibit 13: Antibiotic prophylaxis regimens in several PIDDs
Exhibit 14: Global PIDDs treatment market by others 2016-2021 ($ millions)
Exhibit 15: Segmentation of global PIDDs treatment market by geography 2016 and 2021
Exhibit 16: Global PIDDs treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: PIDDs treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: PIDDs treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: PIDDs treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Fractionation capacities of key vendors
Exhibit 24: Various side effects associated with immunoglobulin therapy
Exhibit 25: Factors contributing to overall cost of production for IVIG
Exhibit 26: Detailed information regarding processes required for TGA approval
Exhibit 27: Fractionating capacities globally in 2007 and 2012
Exhibit 28: Competitive structure analysis of global PIDDs treatment market 2016
Exhibit 29: Competitive factors of global PIDDs treatment market
Exhibit 30: Market penetration of various PIDDs treatment manufacturers globally 2016
Exhibit 31: Strategic success factors of companies in global PIDDs treatment market
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Grifols: Key highlights
Exhibit 37: Grifols: Strength assessment
Exhibit 38: Grifols: Strategy assessment
Exhibit 39: Grifols: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment



【掲載企業】

CSL Behring, Grifols, Pfizer, Shire, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.


【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[原発性免疫不全症治療の世界市場2017-2021:イムノグロブリン治療、抗生物質、その他]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆